Rep. David Taylor Sells Off Amgen Inc. (NASDAQ:AMGN) Stock

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on August 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 8/14/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/11/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 7/24/2026.

Amgen Stock Performance

Shares of AMGN stock opened at $437.23 on Tuesday. The company’s fifty day moving average price is $398.92 and its 200-day moving average price is $367.59. The stock has a market cap of $236.38 billion, a PE ratio of 27.17, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $447.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the business earned $6.02 EPS. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts expect that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen continues to be viewed as a long-term growth candidate, supported by its diversified drug portfolio and potential pipeline contributions. However, the bullish commentary is largely based on broad fundamental and valuation screens rather than a new company-specific announcement. Why Amgen Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: An industry report identified Amgen, Roche and Johnson & Johnson as leading participants in the expanding oncology bi/multispecific-drug market. The report offers sector context but does not announce a new Amgen asset, deal or clinical result, so its immediate effect on AMGN is likely limited. Bi/Multispecific Oncology Market Report
• Neutral Sentiment: Congressman David Taylor disclosed several trades, including sales of biotech holdings. These transactions are not directly linked to Amgen’s operations or outlook and do not provide a meaningful fundamental signal for AMGN. Congressional Stock Trades
• Negative Sentiment: Novartis reported that its Phase III pelacarsen study failed to reduce cardiovascular events, despite testing a lower target biomarker level. Investors are concerned that the result may challenge the broader “lipoprotein(a)” treatment mechanism and make it harder for Amgen’s 7,297-patient olpasiran outcome trial to produce a positive result. Amgen Shares Fall as Pelacarsen Misses Phase III Goal
• Negative Sentiment: The pelacarsen failure prompted a pullback in Amgen shares as investors reassessed olpasiran’s probability of success and potential commercial value. The concern is currently a pipeline-risk repricing, not evidence that Amgen’s approved products or recent earnings performance have deteriorated. Amgen’s 7,297-Patient Heart Bet Inherited a Higher Bar

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock valued at $2,540,926 in the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Parkside Financial Bank & Trust lifted its position in Amgen by 4.1% during the second quarter. Parkside Financial Bank & Trust now owns 4,153 shares of the medical research company’s stock valued at $1,504,000 after purchasing an additional 163 shares during the period. Range Advisory LLC grew its position in Amgen by 38.8% in the 2nd quarter. Range Advisory LLC now owns 1,680 shares of the medical research company’s stock worth $608,000 after purchasing an additional 470 shares during the period. Brown Lisle Cummings Inc. raised its stake in Amgen by 0.3% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 24,121 shares of the medical research company’s stock valued at $8,735,000 after buying an additional 80 shares during the last quarter. Cornerstone Financial Management LLC raised its stake in Amgen by 7.2% during the 2nd quarter. Cornerstone Financial Management LLC now owns 459 shares of the medical research company’s stock valued at $166,000 after buying an additional 31 shares during the last quarter. Finally, HORAN Wealth LLC boosted its stake in shares of Amgen by 1.9% in the 2nd quarter. HORAN Wealth LLC now owns 15,478 shares of the medical research company’s stock worth $5,605,000 after buying an additional 284 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on AMGN shares. Morgan Stanley restated an “overweight” rating and issued a $362.00 price target on shares of Amgen in a research note on Wednesday, August 19th. Mizuho lifted their price objective on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. Truist Financial boosted their target price on Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Canaccord Genuity Group increased their target price on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Finally, Argus lifted their price target on Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $381.68.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.